Literature DB >> 17211696

Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.

Peter Reber1, Rudolf Brenneisen, Beatrice Flogerzi, Catarina Batista, Peter Netzer, Ulrich Scheurer.   

Abstract

The effect of the opioid antagonists naloxone-3-glucuronide and N-methylnaloxone on rat colon motility after morphine stimulation was measured. The rat model consisted of the isolated, vascularly perfused colon. The antagonists (10(-4) M, intraluminally) and morphine (10(-4) M, intra-arterially) were administered from 20 to 30 and from 10 to 50 min, respectively. Colon motility was determined by the luminal outflow. The antagonist concentrations in the luminal and venous outflow were measured by high-performance liquid chromatography. Naloxone-3-glucuronide and N-methylnaloxone reversed the morphine-induced reduction of the luminal outflow to baseline within 10 and 20 min, respectively. These antagonists were then excreted in the luminal outflow and could not be found in the venous samples. Naloxone, produced by hydrolysis or demethylation, was not detectable. In conclusion, highly polar naloxone derivatives peripherally antagonize the motility-lowering effect of morphine in the perfused isolated rat colon, are stable, and are not able to cross the colon-mucosal blood barrier.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211696     DOI: 10.1007/s10620-006-9563-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  Incidence, prevalence, and management of opioid bowel dysfunction.

Authors:  M Pappagallo
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

Review 2.  Side effects of morphine administration in cancer patients.

Authors:  G Vanegas; C Ripamonti; A Sbanotto; F De Conno
Journal:  Cancer Nurs       Date:  1998-08       Impact factor: 2.592

3.  Studies on the viability of the isolated vascularly perfused rat colon.

Authors:  C Herrmann-Rinke; R Eissele; R Arnold; B Göke
Journal:  Digestion       Date:  1996       Impact factor: 3.216

4.  Morphine modulates inducible nitric oxide synthase expression and reduces pulmonary oedema induced by alpha-naphthylthiourea.

Authors:  Mustafa Comert; Emine Yilmaz Sipahi; Huseyin Ustun; Fulden Isikdemir; Gamze Numanoglu; Figen Barut; Hanife Altunkaya; Yetkin Ozer; Ferruh Niyazi Ayoglu; Tunc Hakan Sipahi; Ishak Ozel Tekin; Z Nur Banoglu
Journal:  Eur J Pharmacol       Date:  2005-03-28       Impact factor: 4.432

5.  Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons.

Authors:  Alice Meunier; Alban Latrémolière; Annie Mauborgne; Sylvie Bourgoin; Valérie Kayser; François Cesselin; Michel Hamon; Michel Pohl
Journal:  Mol Ther       Date:  2005-04       Impact factor: 11.454

Review 6.  Morphine metabolites.

Authors:  L L Christrup
Journal:  Acta Anaesthesiol Scand       Date:  1997-01       Impact factor: 2.105

7.  The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

Authors:  C S Yuan; J F Foss; J Osinski; A Toledano; M F Roizen; J Moss
Journal:  Clin Pharmacol Ther       Date:  1997-04       Impact factor: 6.875

8.  Use of a modified symptom distress scale in assessment of the cancer patient.

Authors:  S Holmes
Journal:  Int J Nurs Stud       Date:  1989       Impact factor: 5.837

9.  Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites.

Authors:  S E Bartlett; P R Dodd; M T Smith
Journal:  Pharmacol Toxicol       Date:  1994-08

10.  Cyclooxygenase inhibitors affect Met-enkephalin- and acetylcholine-stimulated motility of the isolated rat colon.

Authors:  U Scheurer; E Drack; F Halter
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

View more
  7 in total

Review 1.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

2.  The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study.

Authors:  Constance L Monitto; Sabine Kost-Byerly; Elizabeth White; Carlton K K Lee; Michelle A Rudek; Carol Thompson; Myron Yaster
Journal:  Anesth Analg       Date:  2011-09-02       Impact factor: 5.108

3.  Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers.

Authors:  Azmi F Nasser; Christian Heidbreder; Yongzhen Liu; Paul J Fudala
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

Review 4.  Opioid receptors in the gastrointestinal tract.

Authors:  Peter Holzer
Journal:  Regul Pept       Date:  2009-04-02

Review 5.  New approaches to the treatment of opioid-induced constipation.

Authors:  P Holzer
Journal:  Eur Rev Med Pharmacol Sci       Date:  2008-08       Impact factor: 3.507

Review 6.  Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.

Authors:  Marta Sobczak; Maciej Sałaga; Martin A Storr; Jakub Fichna
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

Review 7.  Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals.

Authors:  Lynn R Webster; Michael Camilleri; Andrew Finn
Journal:  Subst Abuse Rehabil       Date:  2016-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.